Arbutus Biopharma (ABUS) Cash from Operations (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Cash from Operations for 14 consecutive years, with 8110000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Operations rose 39.44% year-over-year to 8110000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34356000.0 (up 41.72% YoY) and the FY2025 annual result came in at 39637000.0, up 38.88% from the prior year.
• Cash from Operations retreated to 8110000.0 in Q1 2026 per ABUS's latest filing, from 4680000.0 in the prior quarter.
• Over the last five years, Cash from Operations for ABUS reached as high as 20619000.0 in Q1 2022 and fell as low as 27301000.0 in Q1 2023.
• A 5-year average of 13758176.47 and a median of 16990000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 215.31% — and 2023, when it tumbled 232.41%.
• Year by year, Cash from Operations stood at 16990000.0 in 2022, then retreated by 1.78% to 17292000.0 in 2023, then surged by 40.35% to 10315000.0 in 2024, then jumped by 54.63% to 4680000.0 in 2025, then tumbled by 73.29% to 8110000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 8110000.0, 4680000.0, and 5817000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.